i actually have more on the line than anyone here. relatively speaking. my holding is very small vs all of you. i have 100k shares. my life is upside down with extreme financial hardship and i desperately want this stock to go up on a major catalyst. i assure you i want a 50% mss orr, an active wildly successful rollover, merck knocking at the door, an alzheimer's miracle and a speedy start to tnbc and on and on.... but having so much at stake, and simply for any significant investment to be honest, i NEED TO know what the prospects are and how the results will compare in the eyes of the fda, bp, serious investors, etc so that i can at least try and properly gauge share price expectations once this thing does get going. at this point i can't just hold forever if i have profit to take, unless i work out some sort of assistance plan vs an inheritance coming down the line. that's not exactly something to rely upon.
meanwhile, the info i posted earlier is INSANELY VALUABLE for any cydy shareholder. you HAVE TO know what your competitive environment looks like and what regulatory processes await. MSS-CRC is getting a bit like MASH/NASH for instance. BP had given up. PD-1 PD-L1 inhibitor assets had fled. now its all back. luckily in this instance, unlike MASH NASH, cytodyn is AHEAD of many players on timelines and the science. the opening is there if they continue to hit their marks under new leadership. this trial, the rollover, the tnbc fallback and upcoming trial, and the separate liver mets study in the works, are all contributing to quite a setup for potential success. but pharma is also always a race. so you need to be looking over your shoulder as a shareholder. so i dig.
these results... AACR and perhaps more importantly ASCO, are HUGE. solid results, VERSUS THE COMPETITIVE ENVIRONMENT, create a buffer for shareholders and could reset the share price for me and others to at least be in a position to consider some different positive options vs what i'm staring at currently with finances.
ALL that info i shared is MASSIVELY MASSIVELY VALUABLE and i hope you will realize that at some point.
meanwhile, the info i posted earlier is INSANELY VALUABLE for any cydy shareholder. you HAVE TO know what your competitive environment looks like and what regulatory processes await. MSS-CRC is getting a bit like MASH/NASH for instance. BP had given up. PD-1 PD-L1 inhibitor assets had fled. now its all back. luckily in this instance, unlike MASH NASH, cytodyn is AHEAD of many players on timelines and the science. the opening is there if they continue to hit their marks under new leadership. this trial, the rollover, the tnbc fallback and upcoming trial, and the separate liver mets study in the works, are all contributing to quite a setup for potential success. but pharma is also always a race. so you need to be looking over your shoulder as a shareholder. so i dig.
these results... AACR and perhaps more importantly ASCO, are HUGE. solid results, VERSUS THE COMPETITIVE ENVIRONMENT, create a buffer for shareholders and could reset the share price for me and others to at least be in a position to consider some different positive options vs what i'm staring at currently with finances.
ALL that info i shared is MASSIVELY MASSIVELY VALUABLE and i hope you will realize that at some point.
14
1
